



Klinik für Urologie: Erfasste Publikationen aus 2025

ID: 604234

Gegenwärtige und zukünftige Therapiestratifizierung des metastasierten Urothelkarzinoms: eine große Chance für eine echte Präzisionsonkologie

Aktuelle Urol 2025; (); ; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=

Niegisch G, Zschaebitz S, Kluemper N, Eckstein M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606034

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Ann Oncol 2025; 36(8): 988-998; Impact Factor=n.a.; Impact Factor 2024=65.4; Typ=Journal

Article;Multicenter Study;Randomized Controlled Trial;Comparative Study;

Grimm MO, Bedke J, Nyarangi-Dix J, Khoder W, Foller S, Sommerfeld HJ, **Giessing M**, Heck M, Meißner W, Slee A, Leucht K, von Rundstedt F, Theil G, Buse S, Siemer S, **Albers P**, Gratzke C, Hohenfellner M, Stenzl A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606032

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Ann Oncol 2025; 36(7): 796-806; Impact Factor=n.a.; Impact Factor 2024=65.4; Typ=Journal

Article;Randomized Controlled Trial;Clinical Trial, Phase II;Comparative Study;

Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, **Niegisch G**, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602776

Matched-pair analysis of peri-operative and oncological outcomes of robot-assisted vs open retroperitoneal lymph node dissection.

BJU Int 2025; 136(1): 150-158; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Journal

Article;Comparative Study;

Pongratanakul P, **Vermeulen-Spohn M**, **Wöltjen C**, **Thy S**, **Hiestler A**, **Albers P**, **Che Y**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 609321

Emerging tools for the early detection of prostate cancer.

BJUI Compass 2025; 6(9); ; Impact Factor=n.a.; Impact Factor 2024=1.9; Typ=Journal Article;Review;

Haider M, Leow JJ, Nordström T, Mortezaei A, **Albers P**, Heer R, Rajan P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 605799

Psychosocial outcomes of risk-adapted prevention for prostate cancer predisposition: study protocol for a longitudinal observational mixed-methods study.

BMJ Open 2025; 15(7); ; Impact Factor=n.a.; Impact Factor 2024=2.3; Typ=Journal Article;

Klett MK, **Albers P**, **Lakes J**, **Niegisch G**, Antoch G, Boschheidgen M, Dinger U, Fehm T, Jäger B, Redler S, Wieczorek D, Schäfer R, Carl G, Karger A
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 604201

BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF- β and FGF Signaling.

Biology (Basel) 2025; 14(6): ; Impact Factor=n.a.; Impact Factor 2024=3.5; Typ=Journal Article;

Taday R, Jungbluth P, Zensen S, Krakau T, Windolf J, **Hoffmann MJ**, Grotheer V

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 611358

Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.

Cancer Immunol Immunother 2025; 74(12): ; Impact Factor=n.a.; Impact Factor 2024=5.1;

Typ=Journal Article;Multicenter Study;

Váradí M, Horváth O, Soós E, Csizmarik A, Németh B, Gyórfy B, Kenessey I, Reis H, Koll F, Oláh C, Hadaschik B, Krafft U, Grünwald V, Mairinger F, Wessolly M, **Hoffmann MJ**, **Grünwald CM**, **Niegisch G**,

Cotarello CL, Maráz A, Kuthi L, Szász AM, Herold Z, Posta M, Bártai B, Nyirády P, Szarvas T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603316

Repurposing Amiodarone for Bladder Cancer Treatment.

Cancer Res Commun 2025; 5(6): 906-920; Impact Factor=n.a.; Impact Factor 2024=3.3; Typ=Journal Article;

Roa FJ, Roubelakis M, Paschidis K, van Creijl NCH, Handle F, Makridakis M, Narayanasamy S, Balaur IA, Tserga A, Vlahou A, Santer FR, Holm PS, **Hoffmann M**, Puhr M, Mokou M, Frantzi M, Schneider R, Latosinska A, Mischak H, Satagopam V, Culig Z, Pichler R

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614829

Analysis of Operator Expertise in MRI/TRUS Fusion-Guided Prostate Biopsy.

Cancers (Basel) 2025; 17(23): ; Impact Factor=n.a.; Impact Factor 2024=4.4; Typ=Journal Article;

Al-Monajjed R, Schimmöller L, **Lakes J**, **Herzum A**, **Hübner A**, **Bußhoff I**, Ullrich T, Ljimini A, Esposito I, **Albers P**, Antoch G, **Radtke JP**, Boschheidgen M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 611343

Upstaging of Patients Diagnosed with Favorable Intermediate-Risk Prostate Cancer-Is Active Surveillance Really a Suitable Approach for All These Patients?

Cancers (Basel) 2025; 17(21): ; Impact Factor=n.a.; Impact Factor 2024=4.4; Typ=Journal Article;

Handke AE, Orf C, Dellino M, Garcia-Schürmann LM, **Radtke JP**, Noldus J, Roghmann F, Palisaar RJ, Berg S, Tully KH

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 605090

RNF20/RNF40 supports the aggressive behavior in cervical cancer by regulating a peroxisome-based anti-ferroptotic mechanism.

Cell Commun Signal 2025; 23(1): ; Impact Factor=n.a.; Impact Factor 2024=8.9; Typ=Journal Article;

Jansari S, Blandau A, **Prokakis E**, Grimm D, Naßl AM, Küffer S, Möbius W, Dullin C, Ramos-Gomes F, Schürhüis L, Fritsche L, Schridde L, Plessner M, Bast CA, Gayer FA, Thoms S, Gallwas J, Wegwitz F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 610318

Neolactotetraosylceramide enables urinary detection of bladder cancer.

Cell Rep Med 2025; 6(8): ; Impact Factor=n.a.; Impact Factor 2024=10.6; Typ=Journal Article;
Moreira IB, Rossdam C, Kaynert J, Beimdiek J, Vicente MM, Schmitz J, Großhennig A, Oberbeck A,
Hoffmann MJ, Rosero Moreno ME, Steinbach D, Barcena ML, Lippka Y, Bräsen JH, Tezval H, Buettner
FFR

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606285

Comparison of MemoKath™ ureteral stent versus tumor ureteral stent: A single-center long-term analysis

Cent European J Urol 2025; 78(2): 237-243; Impact Factor=n.a.; Impact Factor 2024=1.9; Typ=
Wahl M, Mahmud O, Krafft U, Darr C, **Radtke JP**, Hadaschik B, Panic A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 610969

Electronic Health Literacy, Psychological Distress, and Quality of Life in Urological Cancer Patients: A Longitudinal Study During Transition from Inpatient to Outpatient Care.

Curr Oncol 2025; 32(11): ; Impact Factor=n.a.; Impact Factor 2024=3.4; Typ=Journal
Article;Observational Study;

Fugmann D, Holsteg S, Schäfer R, **Niegisch G**, Dinger U, Karger A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 607094

The Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift.

Dtsch Arztebl Int 2025; 122(15): 420-426; Impact Factor=n.a.; Impact Factor 2024=7.2; Typ=Journal
Article;Review;

Albers P, Franiel T, Koetter T, Kristiansen G, Herrmann K, Wiegel T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 607621

The Probability of Remaining Under Active Surveillance for Localized Prostate Cancer: An Analysis of Young Patients in the Framework of the Multicenter ProjuMa Registry Study.

Dtsch Arztebl Int 2025; 122(15): 401-405; Impact Factor=n.a.; Impact Factor 2024=7.2; Typ=Journal
Article;Multicenter Study;Observational Study;

Claassen K, Justenhoven C, Hermann S, Brandhorst J, Lakes J, Werner D, Kajüter H, Karpinski M,
Arndt V, Stang A, Albers P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603297

Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer.

EJNMMI Res 2025; 15(1): ; Impact Factor=n.a.; Impact Factor 2024=3.0; Typ=Journal Article;

Mamlins E, Novruzov E, Watabe T, Mori Y, Dabir M, Mattes-György K, Antke C, Henke J, Boschheidgen
M, Kirchner J, Jazmati D, Hausmann J, **Radtke JP**, **Niegisch G**, Cardinale J, Hörner-Rieber J, **Albers
P**, Antoch G, Giesel FL, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599814

Immune training enhances anti-viral responses and improves outcomes in Pax5^{-/+} mice susceptible to chronic infection.

EMBO Mol Med 2025; 17(4): 696-721; Impact Factor=n.a.; Impact Factor 2024=8.3; Typ=Journal Article; Lu Z, Stencel O, Liu W, Vasileiou E, Xu HC, Pandey P, Stachura P, Elwy A, Tsombal A, Mai AS, Auer F, Morcos MNF, **Seidl M**, Koziel S, Bruch PM, Dietrich S, Elitzur S, Hartmann G, Lang KS, Janssen S, Fischer U, Bhatia S, Lang PA, Borkhardt A, Hauer J, Pandya AA
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614872

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis

ESMO Real World Data Digit. Oncol. 2025; 8(): ; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Article;

Stelmach R, Erdmann S, Schlack K, Muehle C, Darr C, Neuberger S, Reichert M, Flegar L, Egenolf T, **Rehlinghaus M**, Zengerling F, Casuscelli J, Cox A, Vallet S, Nestler T, Brehmer B, Ivanyi P, Paffenholz P, Neuberger M, Jager D, Grunwald V, Zschabitz S

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 610125

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

Eur J Nucl Med Mol Imaging 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=7.6; Typ=Journal Article;

Giesel FL, Koerber SA, Hadaschik B, Kiefer S, Schwarzenboeck S, Rahbar K, Derlin T, Grott CA, Heck M, Jilg C, Meyer PT, Ruf J, Schmidt K, Kotzerke J, la Fougère C, Reischl G, Virgolini I, Herrmann K, Burger IA, Lorenzini T, Werner M, Stenzinger A, Schwamborn K, **Radtke JP**, Hohenfellner M, Debus J, Weber WA, Haberkorn U, Kopka K, Eiber M, 68Ga-PSMA-11 DKTK trial contributors

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571990

MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.

Eur Radiol 2025; 35(4): 2170-2179; Impact Factor=n.a.; Impact Factor 2024=4.7; Typ=Journal Article; Boschheidgen M, Schimmöller L, **Radtke JP**, Kastl R, Jannusch K, **Lakes J**, Drewes LR, Radke KL, Esposito I, **Albers P**, Antoch G, Ullrich T, **Al-Monajjed R**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602457

Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review.

Eur Urol 2025; 87(4): 427-441; Impact Factor=n.a.; Impact Factor 2024=25.2; Typ=Systematic Review;Journal Article;Review;

Tateo V, Thompson ZJ, Gilbert SM, Cortessis VK, Daneshmand S, Masterson TA, Feldman DR, Pierorazio PM, Prakash G, Heidenreich A, **Albers P**, Necchi A, Spiess PE

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 613648

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Eur Urol 2025; 88(6): 566-570; Impact Factor=n.a.; Impact Factor 2024=25.2; Typ=Journal Article;Randomized Controlled Trial;Multicenter Study;Clinical Trial, Phase III;Comparative Study;

Heck MM, Lehmann J, Amiel T, Rübber H, **Albers P**, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer

T, Rexer H, Retz M, Gschwend JE

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 607641

Magnetic Resonance Imaging-based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review.

Eur Urol 2025; 88(3): 247-260; Impact Factor=n.a.; Impact Factor 2024=25.2; Typ=Journal

Article;Systematic Review;Review;

Schoots IG, Ahmed HU, **Albers P**, Asbach P, van den Bergh RCN, Godtman RA, van Leeuwen PJ, Nordström T, Punwani S, Wallström J, Padhani AR

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603082

Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.

Eur Urol 2025; 88(3): 240-244; Impact Factor=n.a.; Impact Factor 2024=25.2; Typ=Journal Article;

Al-Monajjed R, Boschheidgen M, **Lakes J**, Krilaviciute A, **Radtke JP**, Schlemmer HP, Bonekamp D, Herkommer K, Jahnen M, Gschwend JE, Dux D, Wacker F, Makowski MR, Sauter A, Kuczyk MA, Harke N, Debus J, Grott C, **Arsov C**, Seibold P, Hadaschik B, Giesel F, Kristiansen G, Antoch G, Becker N, Kaaks R, Schimmöller L, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614717

Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial.

Eur Urol 2025; 88(6): 636-637; Impact Factor=n.a.; Impact Factor 2024=25.2; Typ=Journal Article;

Albers P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606375

Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional Collaboration.

Eur Urol Focus 2025; 11(6): 921-925; Impact Factor=n.a.; Impact Factor 2024=5.6; Typ=Journal Article;Multicenter Study;Comparative Study;

Bravi CA, Knipper S, Heidenreich A, Fossati N, Gandaglia G, Dell'Oglio P, Suardi N, Osmonov D, Juenemann KP, Karnes J, Kretschmer A, Budäus L, Falkenbach F, Buchner A, Stief C, **Hiester A**, **Albers P**, Devos G, Joniau S, Poppel HV, Grubmüller B, Shariat S, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Montorsi F, Briganti A, Maurer T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606016

Capillary Blood for Prostate-specific Antigen Testing: The PSA-CAP Study.

Eur. Urol. Open Sci. 2025; 78(): 28-31; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Letter;

Wallisch M, **Albers P**, Becker N, Boege F, Hermsen D, Londhe TR, **Lakes J**, **Radtke JP**, Krilaviciute A, Seibold P, Benner A, Saadati M, Holdenrieder S, **Al-Monajjed R**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602843

Characterisation of Multiparametric Magnetic Resonance Imaging of the Prostate in Younger Men with Normal Prostate-specific Antigen Within the PROBASE Study.

Eur. Urol. Open Sci. 2025; 75(): 94-100; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Journal

Article;

Al-Monajjed R, Schimmöller L, **Radtke JP**, **Lakes J**, Krilaviciute A, Schlemmer HP, Herkommer K, Seibold P, Becker N, Kaaks R, Hadaschik B, Antoch G, **Albers P**, Boschheidgen M
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 606278

Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project.

Eur. Urol. Open Sci. 2025; 78(): 59-67; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Journal Article;

Hilser T, Casuscelli J, Aydogdu C, Zschäbitz S, Schnabel MJ, Rinderknecht E, Mattigk A, Schostak M, Volk AL, Ivanyi P, Wiegmann J, Darr C, Flegar L, Mandal S, Schlack K, Seidl D, Handke A, Klee M, Nestler T, **Rehlinghaus M**, Hijazi S, Heidenreich A, Grünwald V, Paffenholz P
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602430

Screening for Prostate Cancer with Prostate-specific Antigen.

Eur. Urol. Open Sci. 2025; 74(): 71-72; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Journal Article;

Al-Monajjed R, **Albers P**, Hadaschik B

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603291

Promoting interdisciplinarity and the timely integration of palliative care through the development and implementation of a blended learning elective for medical students.

GMS J Med Educ 2025; 42(2): ; Impact Factor=n.a.; Impact Factor 2024=1.7; Typ=Journal Article;

Batzler YN, Schallenburger M, Sammer T, Haussmann J, Tamaskovics B, **Rehlinghaus M**, von Schreitter J, Otten S, Fohler C, Schwartz J, Karger A, **Niegisch G**, Neukirchen M
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599798

Induction of SOX17 with stimulation of WNT, TGF-beta, and FGF signaling drives embryonal carcinomas into the yolk-sac tumor lineage resulting in increased cisplatin resistance.

Int J Cancer 2025; 156(11): 2210-2224; Impact Factor=n.a.; Impact Factor 2024=4.7; Typ=Journal Article;

Kotthoff M, **Skowron MA**, Bremmer F, **Parmaksiz F**, **Kretschmer P**, **Stephan A**, Fichtner A, Lautwein T, Raba K, Fuß J, Köhrer K, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614797

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Int J Cancer 2025; (); ; Impact Factor=n.a.; Impact Factor 2024=4.7; Typ=Journal Article;

Dinkel H, Materna L, Stelmach R, Zschäbitz S, Neuberger S, Aydogdu CD, Casuscelli J, Egenolf T, Silberg M, Steinestel J, Strauss A, Kirchhoff F, Ahrens M, Paffenholz P, Cathomas R, Özdemir BC, Gossler C, Ivanyi P, **Rehlinghaus M**, Hilser T, Grünwald V, Schlack K
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603819

Correction: Sturm et al. Exposure of Bladder Cancer Cells to Blue Light ($\lambda = 453 \text{ nm}$) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. *Int. J. Mol. Sci.* 2024, 25,

4868.

Int J Mol Sci 2025; 26(10): ; Impact Factor=n.a.; Impact Factor 2024=4.9; Typ=Published Erratum;
Sturm S, **Niegisch G**, Windolf J, Suschek CV
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599826

Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial.

J Behav Med 2025; 48(3): 464-477; Impact Factor=n.a.; Impact Factor 2024=2.9; Typ=Journal Article;
Meissner VH, Dinkel A, Kron M, Schiele S, Jahnen M, **Lakes J**, **Radtke JP**, Kuczyk MA, Harke NN, Debus J, Fink CA, Antoch G, Schimmöller L, Kristiansen G, Krilaviciute A, Seibold P, Behrens S, Benner A, **Arsov C**, Hadaschik B, Becker N, Kaaks R, **Albers P**, Gschwend JE, Herkommer K
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 586970

Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic.

J Cancer Res Clin Oncol 2025; 151(1): ; Impact Factor=n.a.; Impact Factor 2024=2.8; Typ=Published Erratum;

Arndt V, Doege D, Fröhling S, **Albers P**, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levezow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 565612

Spectral Diffusion Analysis in Patients With High Risk for Prostate Cancer: A Feasibility Study.

J Magn Reson Imaging 2025; 61(1): 512-515; Impact Factor=n.a.; Impact Factor 2024=3.5; Typ=Letter;
Thiel TA, Valentin B, Ullrich T, Boschheidgen M, Schimmöller L, Benkert T, **Al-Monajjed R**, Ljimini A, Antoch G, Jasse J, Bechler E, Wittsack HJ
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 609310

Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.

JAMA 2025; 334(13): 1170-1179; Impact Factor=n.a.; Impact Factor 2024=55.0; Typ=Journal Article;Multicenter Study;Comparative Study;Equivalence Trial;Comment;

Ng ABCD, Asif A, Agarwal R, Panebianco V, Girometti R, Ghai S, Gómez-Gómez E, Budäus L, Barrett T, **Radtke JP**, Kesch C, De Cobelli F, Pham T, Taneja SS, Hu JC, Tewari A, Rodríguez Cabello MÁ, Dias AB, Mynderse LA, Borghi M, Boesen L, Singh P, Renard-Penna R, Leow JJ, Falkenbach F, Pecoraro M, Giannarini G, Perlis N, López-Ruiz D, Kastner C, Schimmöller L, Rossiter M, Nathan A, Khetrapal P, Chan VW, Haider A, Clarke CS, Punwani S, Brew-Graves C, Dickinson L, Mitra A, Brembilla G, Margolis DJA, Takwoingi Y, Emberton M, Allen C, Giganti F, Moore CM, Kasivisvanathan V, PRIME Study Group Collaborators

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599848

Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission.

Magn Reson Imaging 2025; 118(): ; Impact Factor=n.a.; Impact Factor 2024=2.0; Typ=Journal Article;Comparative Study;

Boschheidgen M, Drewes L, Valentin B, Ullrich T, Trappe S, **Al-Monajjed R**, **Radtke JP**, **Albers P**,

Wittsack HJ, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 611336

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.

Mol Oncol 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=4.5; Typ=Journal Article;

Schmitz J, Bartkowiak AL, Rose M, Kolks N, Petzsch P, Solanki V, Stoffel A, Faßbender B, Lepping L, Volkamer J, Köhrer K, Seifert M, Mahmoudi T, Zuiverloon TCM, Niegisch G, Hoffmann MJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 577878

Low income, being without employment, and living alone: how they are associated with cognitive functioning-Results from the German national cohort (NAKO).

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2025; 32(4): 542-557; Impact Factor=n.a.; Impact Factor 2024=1.6; Typ=Journal Article;

Rodriguez FS, Röhr S, **Dragano N**, Schmidt B, Becher H, Schikowski T, Gastell S, Harth V, Hoven H, Linseisen J, Greiser KH, Leitzmann M, Bohmann P, Castell S, Heise JK, Krist L, Keil T, Karch A, Teismann H, Moreno Velásquez I, Pischon T, Peters A, Führer A, Mikolajczyk R, Günther K, Brand T, Meinke-Franze C, Schipf S, Grabe HJ, Brenner H, Koch-Gallenkamp L, Berger K, Wagner M, Katzke V, Lieb W, Pabst A, Riedel-Heller SG

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 575242

Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care.

Oncology Research and Treatment 2025; 48(1-2): 4-13; Impact Factor=n.a.; Impact Factor 2024=1.7; Typ=Journal Article;Observational Study;

Fugmann D, Holsteg S, Schäfer R, Kreuznacht L, Speer D, **Niegisch G**, Dinger U, Karger A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603807

Early detection and modern imaging diagnostics of prostate cancer

Onkologie (Heidelberg, Germany) 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=0.2; Typ=Review; Early Access;

Busshoff I, Huebner A, Al-Monajjed R, Lakes J, Radtke JP, Albers P

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 609210

Patient-reported outcomes in robotic surgery-where do we stand in urology and senology?

Onkologie (Heidelberg, Germany) 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=0.2; Typ=Review; Early Access;

Sibert NT, Fehm TN, **Albers P**, Hentsch S

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 602446

[Challenges in the research and diagnosis of rare diseases].

Pathologie (Heidelb) 2025; 46(3): 142-151; Impact Factor=n.a.; Impact Factor 2024=0.7; Typ=English Abstract;Journal Article;

Marx A, Ströbel P, Bremmer F, **Nettersheim D**, Rupp NJ, Wardelmann E, Hartmann W

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 609296

Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy.

Prostate Cancer Prostatic Dis 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=5.8; Typ=Journal Article;Review;

Lakes J, **Al-Monajjed R**, **Busshoff I**, **Hübner A**, Boschheidgen M, Valentin B, Antoch G, **Albers P**, Schimmöller L, **Radtke JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 601293

Evaluation of the current status, significance, and availability of prostate MRI und MRI guided biopsy in Germany.

Rofo 2025; 197(8): 945-952; Impact Factor=n.a.; Impact Factor 2024=1.7; Typ=Journal Article;

Ullrich T, Boschheidgen M, Schweyen CM, Franiel T, Valentin B, Quentin M, Blondin D, Kaufmann S, Ljimini A, **Radtke JP**, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 588201

Squared diffusion-weighted imaging for improving the detection of clinically significant prostate cancer.

Sci Rep 2025; 15(1): ; Impact Factor=n.a.; Impact Factor 2024=3.9; Typ=Journal Article;

Valentin B, Schimmöller L, Boschheidgen M, Ullrich T, Thiel TA, Ljimini A, **Radtke JP**, Benkert T, **Albers P**, Antoch G, Wittsack HJ, Quentin M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614846

The AUO

Urologie 2025; 64(12): ; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=

Rexer H, **Che Y**, Pfister D

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 607653

[Current developments in surgery and radiotherapy for the treatment of seminoma stage IIA/B].

Urologie 2025; 64(10): 1018-1023; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=English

Abstract;Journal Article;Review;

Che Y, **Papachristofilou A**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 576215

[Early detection of prostate cancer-individualized, risk-adapted and successful].

Urologie 2025; 64(1): 14-23; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=English Abstract;Journal Article;Review;

Hübner A, **Bußhoff I**, **Lakes J**, **Al-Monajjed R**, **Radtke JP**, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 609159

[New insights from basic research on testicular germ cell tumors and updated tumorigenesis].

Urologie 2025; 64(10): 1055-1063; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=English Abstract;Journal Article;Review;

Skowron MA, **Schneider L**, **Prokakis E**, Fichtner A, Nestler T, Bremmer F, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599822

[Objectives of screening and early detection in medicine].

Urologie 2025; 64(1): 1-3; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=Editorial;
Heidenreich A, **Albers P**, Michel MS
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599810

[Report on the 15th symposium of the German Research Association for Bladder Cancer (DFBK) on 24 and 25 January 2025 in Jena].

Urologie 2025; 64(5): 476-478; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=Journal Article;
Ecke TH, Steinbach D, Becker C, Füssel S, **Hoffmann MJ**, Gaisa NT, Nawroth R
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 603851

[Women in urological research: benefits and opportunities for german urology].

Urologie 2025; 64(8): 825-829; Impact Factor=n.a.; Impact Factor 2024=0.4; Typ=Journal Article;
Hoffmann MJ, Schubert M, Erdmann K, Schneidewind L, Theil G, Freifrau von Brandenstein M, Jüngel E, Junker K
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 599838

Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology.

Urology 2025; 197(): 119-125; Impact Factor=n.a.; Impact Factor 2024=2.0; Typ=Journal Article;Comparative Study;Multicenter Study;

Ecke TH, Meisl CJ, Schlomm T, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T, **Grunewald CM**, **Niegisch G**, Hennig MJP, Kramer MW, Koch S, Roggisch J, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM, Klatte T
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 614777

Thoracic residual germ cell tumor resection after high-dose chemotherapy with autologous stem cell transplantation in relapsed patients.

World J Urol 2025; 44(1): ; Impact Factor=n.a.; Impact Factor 2024=2.9; Typ=Journal Article;
Sponholz S, Karaindros G, Ntelli KC, Schirren M, **Albers P**, **Che Y**, Lorch A, Walles T, Fisseler-Eckhoff A, Schirren J
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

